Table 3.
The prevalence of BRAFV600E and TERT promoter mutations in different ATA and TNM stages.
| Wild BRAF
No. (%) |
BRAFV600E
No. (%) |
P value | Wild TERT
No. (%) |
TERT promoter No. (%) |
P value | |
|---|---|---|---|---|---|---|
| ATA staging | ||||||
| Low risk | 54 (56.2) | 42 (43.8) | 0.33 | 74 (77.1) | 22 (22.9) | 0.007 |
| Intermediate risk | 61 (48.8) | 64 (51.2) | 103 (82.4) | 22 (17.6) | ||
| High risk | 44 (58.7) | 31 (41.3) | 47 (62.7) | 28 (37.3) | ||
| TNM staging | ||||||
| I | 55 (55.6) | 44 (44.4) | 0.41 | 96 (97.0) | 3 (3.0) | <0.001 |
| II | 77 (51.3) | 73 (48.7) | 104 (69.3) | 46 (30.7) | ||
| III | 18 (66.7) | 9 (33.3) | 19 (70.4) | 8 (29.6) | ||
| IV | 9 (45) | 11 (55) | 5 (25) | 15 (75) | ||